HRTX - Heron Therapeutics Inc Stock Price, Fair Value and News

2.89USD+0.12 (+4.33%)Delayed as of 18 Apr 2024, 11:55 am ET

Market Summary

USD2.89+0.12

Delayedas of 18 Apr 2024, 11:55 am

4.33%

HRTX Stock Price

View Fullscreen

HRTX RSI Chart

HRTX Valuation

Market Cap

416.4M

Price/Earnings (Trailing)

-3.77

Price/Sales (Trailing)

3.28

EV/EBITDA

-59.55

Price/Free Cashflow

-6.9

HRTX Price/Sales (Trailing)

HRTX Profitability

EBT Margin

-9.00%

Return on Equity

325.43%

Return on Assets

-49.69%

Free Cashflow Yield

-14.49%

HRTX Fundamentals

HRTX Revenue

Revenue (TTM)

127.0M

Rev. Growth (Yr)

14%

Rev. Growth (Qtr)

8.9%

HRTX Earnings

Earnings (TTM)

-110.6M

Earnings Growth (Yr)

46.03%

Earnings Growth (Qtr)

57.12%

Breaking Down HRTX Revenue

52 Week Range

0.932.96

(Low)(High)

Last 7 days

1.5%

Last 30 days

-6.4%

Last 90 days

32.5%

Trailing 12 Months

3.4%

How does HRTX drawdown profile look like?

HRTX Financial Health

Current Ratio

2.37

HRTX Investor Care

Shares Dilution (1Y)

26.05%

Diluted EPS (TTM)

-0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	113.8M	118.0M	122.8M	127.0M
2022	89.8M	95.0M	98.3M	107.7M
2021	83.3M	83.0M	86.3M	86.3M
2020	139.8M	125.8M	103.1M	88.6M
2019	97.5M	116.9M	139.7M	146.0M
2018	38.7M	47.5M	58.7M	77.5M
2017	4.9M	13.4M	22.0M	30.8M
2016	0	0	0	1.5M
2011	1.5M	1.2M	825.0K	646.0K
2010	0	1.3M	1.3M	1.3M
2009	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Heron Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	collard craig a	acquired	-	-	62,500	chief executive officer
Jan 19, 2024	christian waage	acquired	-	-	13,948	-
Jan 19, 2024	johnson craig a	acquired	-	-	13,948	-
Jan 19, 2024	rodriguez susan	acquired	-	-	13,948	-
Jan 19, 2024	dissanaike sharmila	acquired	-	-	13,948	-
Jan 19, 2024	morgan adam	acquired	-	-	13,948	-
Jan 13, 2024	peraza lisa	acquired	-	-	1,841	vp, chief accounting officer
Jan 13, 2024	peraza lisa	sold (taxes)	-1,625	2.15	-756	vp, chief accounting officer
Nov 17, 2023	forbes william p	bought	27,250	1.09	25,000	evp, chief development officer
Nov 16, 2023	forbes william p	bought	46,995	0.9399	50,000	evp, chief development officer

Which funds bought or sold HRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Congress Park Capital LLC	reduced	-8.55	1,498,350	4,556,060	2.02%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	0.03	38,514	99,665	-%
Apr 15, 2024	Future Financial Wealth Managment LLC	new	-	19,390	19,390	0.01%
Apr 15, 2024	Apeiron RIA LLC	added	49.4	202,380	343,480	0.10%
Apr 12, 2024	Gleason Group, Inc.	unchanged	-	7,137	18,476	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	118	305	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	107	277	-%
Apr 12, 2024	DLK Investment Management, LLC	unchanged	-	19,142	49,555	0.02%
Apr 11, 2024	Douglas Lane & Associates, LLC	sold off	-100	-17,000	-	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	300	778	-%

Are Funds Buying or Selling HRTX?

Are funds buying HRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HRTX

No. of Funds

Unveiling Heron Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	great point partners llc	0%	0	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.99%	7,881,933	SC 13G/A
Feb 13, 2024	vanguard group inc	5.56%	8,338,912	SC 13G/A
Feb 06, 2024	franklin resources inc	4.3%	6,404,795	SC 13G/A
Dec 07, 2023	jpmorgan chase & co	0.0%	84,549	SC 13G/A
Dec 06, 2023	blackrock inc.	4.7%	7,037,314	SC 13G/A
Jul 25, 2023	rubric capital management lp	19.0%	26,713,503	SC 13D/A
Apr 13, 2023	great point partners llc	5.35%	6,360,161	SC 13G
Feb 22, 2023	rubric capital management lp	9.9%	11,750,000	SC 13D/A

Recent SEC filings of Heron Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 06, 2024	SC 13G/A	Major Ownership Report
Jan 24, 2024	8-K	Current Report

Peers (Alternatives to Heron Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Heron Therapeutics Inc News

Latest updates

Heron Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	8.9%	34,233	31,434	31,762	29,615	30,028	26,557	27,630	23,457	20,655	23,230	22,443	20,018	20,605	19,965	22,668	25,400	35,083	42,624	36,659	31,602	28,844
Gross Profit	84.1%	24,348	13,226	-	-	-	11,840	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-57.9%	16,062	38,155	74,165	62,678	23,991	53,722	77,128	86,380	74,192	74,938	82,912	72,132	81,901	78,349	78,417	78,134	94,445	77,477	88,438	96,302	80,158
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96,302	80,158
S&GA Expenses	-4.8%	12,328	12,956	21,205	21,154	17,775	18,378	22,938	23,422	24,487	25,206	22,250	15,236	15,553	12,515	15,589	20,196	20,420	16,977	23,647	28,720	19,957
R&D Expenses	-19.2%	10,950	13,558	17,572	13,817	11,057	25,545	28,834	42,070	28,877	28,595	35,233	38,116	44,453	49,182	44,004	36,894	48,277	34,708	41,425	42,972	39,891
EBITDA Margin	11.4%	-0.04*	-0.05*	-0.05*	-0.05*	-0.06*	-0.06*	-0.06*	-0.07*	-0.07*	-0.08*	-0.08*	-0.08*	-	-	-	-	-	-	-	-	-
Interest Expenses	1482.8%	2,580	163	-	-	1,349	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,489
EBT Margin	3.3%	-0.09*	-0.09*	-0.10*	-0.10*	-0.11*	-0.12*	-0.12*	-0.13*	-0.13*	-0.13*	-0.14*	-0.14*	-	-	-	-	-	-	-	-	-
Net Income	57.1%	-10,724	-25,008	-42,059	-32,768	-19,869	-41,908	-56,359	-63,888	-54,646	-52,408	-61,015	-52,614	-62,281	-58,228	-55,190	-51,579	-57,920	-33,595	-50,222	-63,012	-49,559
Net Income Margin	10.7%	-0.87*	-0.97*	-1.16*	-1.33*	-1.69*	-2.21*	-2.39*	-2.58*	-2.56*	-2.65*	-2.82*	-2.74*	-	-	-	-	-	-	-	-	-
Free Cashflow	122.1%	2,205	-9,972	-27,443	-25,124	-37,948	-37,111	-28,695	-44,983	-45,648	-54,697	-63,307	-42,724	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.9%	223	229	201	221	251	272	244	274	306	352	404	311	354	390	433	479	513	393	412	436	462
Current Assets	-2.7%	189	194	165	178	205	224	194	223	254	315	367	272	314	351	393	438	479	364	381	406	447
Cash Equivalents	-17.7%	29.00	35.00	13.00	27.00	15.00	50.00	49.00	57.00	91.00	160	191	60.00	105	95.00	81.00	103	72.00	60.00	53.00	23.00	32.00
Inventory	0.2%	42.00	42.00	45.00	52.00	55.00	52.00	61.00	56.00	48.00	42.00	43.00	43.00	42.00	43.00	41.00	35.00	25.00	24.00	29.00	31.00	39.00
Net PPE	-3.0%	20.00	21.00	21.00	22.00	22.00	23.00	23.00	24.00	24.00	23.00	22.00	23.00	23.00	22.00	22.00	22.00	20.00	16.00	18.00	16.00	15.00
Liabilities	-0.2%	256	257	241	232	237	250	266	250	228	234	244	115	117	113	109	113	109	108	106	104	92.00
Current Liabilities	-0.1%	80.00	80.00	87.00	78.00	82.00	94.00	109	93.00	71.00	72.00	82.00	101	103	98.00	93.00	97.00	97.00	97.00	95.00	92.00	92.00
Shareholder's Equity	-Infinity%	-33.97	-	-	-	14.00	22.00	-	24.00	78.00	119	160	196	236	277	324	365	404	285	305	332	370
Retained Earnings	-0.6%	-1,906	-1,895	-1,870	-1,800	-1,795	-1,775	-1,733	-1,677	-1,613	-1,558	-1,506	-1,445	-1,392	-1,330	-1,272	-1,217	-1,165	-1,107	-1,073	-1,023	-960
Additional Paid-In Capital	0.2%	1,871	1,866	1,830	1,816	1,808	1,797	1,711	1,700	1,690	1,677	1,665	1,641	1,628	1,606	1,594	1,581	1,568	1,392	1,378	1,355	1,330
Accumulated Depreciation	-	17.00	-	-	-	14.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	3.7%	150	145	119	119	119	112	102	102	102	97.00	95.00	91.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	120	-	-	-	285	-	-	-	1,600	-	-	-	1,300	-	-	-	1,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	126.7%	2,455	-9,179	-27,165	-24,900	-37,534	-37,066	-28,373	-43,939	-45,258	-53,166	-62,992	-41,938	-52,554	-42,054	-57,277	-32,935	-26,977	-25,471	-23,108	-49,024	-33,487
Share Based Compensation	-35.3%	4,324	6,683	13,900	7,947	10,514	11,198	10,353	10,915	12,888	11,236	11,241	11,486	16,035	11,095	11,114	11,974	11,099	9,704	12,706	17,902	9,795
Cashflow From Investing	61.9%	-8,836	-23,221	13,218	36,834	2,021	-36,047	19,756	10,946	-24,258	21,634	39,697	-4,344	56,789	55,943	32,408	63,815	-126,359	28,627	41,839	34,110	8,328
Cashflow From Financing	-99.6%	199	53,797	319	-208	439	74,942	315	-637	487	-71.00	154,729	883	5,762	524	2,312	507	165,126	3,914	10,846	6,539	3,061

HRTX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Net product sales	$ 127,044	$ 107,672
Cost of product sales	65,105	54,874
Gross profit	61,939	52,798
Operating expenses:
Research and development	55,897	107,506
General and administrative	49,014	37,437
Sales and marketing	67,643	82,513
Total operating expenses	172,554	227,456
Loss from operations	(110,615)	(174,658)
Other income (expense), net:
Interest income	3,364	1,638
Interest expense	(3,868)	(2,474)
Other income (expense)	560	(6,530)
Total other income (expense), net	56	(7,366)
Net loss	(110,559)	(182,024)
Other comprehensive income (loss):
Unrealized gains (losses) on short-term investments	32	(13)
Comprehensive loss	$ (110,527)	$ (182,037)
Basic net loss per share	$ (0.8)	$ (1.67)
Shares used in computing basic net loss per share	138,135	108,876
Diluted net loss per share	$ (0.8)	$ (1.67)
Shares used in computing diluted net loss per share	138,135	108,876

HRTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,677	$ 15,364
Short-term investments	51,732	69,488
Accounts receivable, net	60,137	52,049
Inventory	42,110	54,573
Prepaid expenses and other current assets	6,118	13,961
Total current assets	188,774	205,435
Property and equipment, net	20,166	22,160
Right-of-use lease assets	5,438	7,645
Other assets	8,128	15,711
Total assets	222,506	250,951
Current liabilities:
Accounts payable	3,240	3,225
Accrued clinical and manufacturing liabilities	22,291	24,468
Accrued payroll and employee liabilities	9,224	13,416
Other accrued liabilities	41,855	38,552
Current lease liabilities	3,075	2,694
Total current liabilities	79,685	82,355
Non-current lease liabilities	2,800	5,499
Non-current notes payable, net	24,263
Non-current convertible notes payable, net	149,490	149,284
Other non-current liabilities	241	241
Total liabilities	256,479	237,379
Commitments and contingencies (see Note 6)
Stockholders’ equity:
Preferred stock, $0.01 par value: 2,500,000 shares authorized; no shares issued or outstanding at December 31, 2023 and 2022
Common stock, $0.01 par value: 225,000,000 shares authorized; 150,285,044 shares issued and outstanding at December 31, 2023 and 119,154,538 shares issued and outstanding at December 31, 2022	1,503	1,191
Additional paid-in capital	1,870,525	1,807,855
Accumulated other comprehensive income (loss)	13	(19)
Accumulated deficit	(1,906,014)	(1,795,455)
Total stockholders' (deficit) equity	(33,973)	13,572
Total liabilities and stockholders’ equity	$ 222,506	$ 250,951

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

CEO	Mr. Craig Alexander Collard
WEBSITE	herontx.com
INDUSTRY	Biotechnology
EMPLOYEES	203

Heron Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Heron Therapeutics Inc? What does HRTX stand for in stocks?

HRTX is the stock ticker symbol of Heron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Heron Therapeutics Inc (HRTX)?

As of Wed Apr 17 2024, market cap of Heron Therapeutics Inc is 416.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HRTX stock?

You can check HRTX's fair value in chart for subscribers.

What is the fair value of HRTX stock?

You can check HRTX's fair value in chart for subscribers. The fair value of Heron Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Heron Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Heron Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HRTX is over valued or under valued. Whether Heron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Heron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRTX.

What is Heron Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, HRTX's PE ratio (Price to Earnings) is -3.77 and Price to Sales (PS) ratio is 3.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Heron Therapeutics Inc's stock?

In the past 10 years, Heron Therapeutics Inc has provided -0.134 (multiply by 100 for percentage) rate of return.